Tysabri Natalizumab

In the phase II trial, all Natalizumab treated MS subjects had fewer relapses and fewer Gd enhancing lesions compared to placebo treated subjects (O Connor et al., 2005). An open label safety and drug interaction study of the use of Natalizumab 

---

Tysabri Natalizumab Biogen Idee Anti-alpha 4 Multiple sclerosis 2005... 

Tysabri natalizumab (2004) Anti-a4 integrin (mAb-IgG4) Multiple sclerosis Cynomolgus monkey (EFD), Guinea pig (F, EFD, PPD)... 

Two drugs initially withdrawn were allowed back by the FDA in U.S. markets. Lotronex (Alosetron, Glaxo Smith Kline) for irritable bowel syndrome was approved in early 2000 and withdrawn 9 months later due to serious gastrointestinal problems. It was reapproved with restrictions in 2002. Tysabri (Natalizumab, Biogen Idee, Elan) for multiple sclerosis was approved in late 2004 and withdrawn in 2005 due to rare fatal brain lesions and was allowed back in mid-2006. 

Figure 1.9 A black box warning from the FDA label for Tysabri (natalizumab), approved June 5, 2006. For illustrative purposes only. (Source FDA.)...

Natalizumab (Tysabri ) is a recombinant humanized IgG4 mAb that binds to the a4-integrin subunit of a4(31 (VLA-4) and oA M (LPAM-1) integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the a4-mediated adhesion of leukocytes to their respective receptors.103 104 The receptor for a4pi, vascular cell adhesion molecule-1 (VCAM-1), is expressed on activated endothelial cells and is... 

Methylphenidate, Transdermal (Daytrana) Modafinil (Provigil) Natalizumab (Tysabri) Nimodipine (Nimotop) Rivastigmine (Exelon)... 

Natalizumab (Tysabri), an anti-a4 integrin monoclonal antibody approved for the treatment of multiple sclerosis, was recently withdrawn from the market temporarily due to cases of progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system associated with immunosuppression [32], These cases highlight our incomplete understanding of the immune system and the translation of preclinical results to humans. 

Natalizumab Tysabri Biogen Idec/Elan humanized mAb VLA4 multiple sclerosis 2004 lgG4 6-10% ... 

Natalizumab Humanized IgG4K NSO a-4 integrin Blocks lymphocyte trafficking MS and Crdm s Tysabri ... 

---